Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV-associated early-stage hepatocellular carcinoma: results from a Dutch long-term follow-up study

J Viral Hepat. 2021 Jan;28(1):205-208. doi: 10.1111/jvh.13394. Epub 2020 Sep 14.

Abstract

Prognosis of hepatitis B (HBV)-associated hepatocellular carcinoma (HCC) is poor due to high rates of HCC recurrence and progression of underlying liver disease. We studied whether serum hepatitis B core-related antigen (HBcrAg) levels could predict HCC recurrence and outcome in HBV associated. Higher HBcrAg levels at HCC diagnosis were independently associated with reduced overall and recurrence-free survival in patients with early, but not advanced, stage HCC.

Keywords: HBcrAg; hepatitis B; hepatocellular carcinoma; survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Hepatocellular* / diagnosis
  • Carcinoma, Hepatocellular* / epidemiology
  • DNA, Viral
  • Follow-Up Studies
  • Hepatitis B Core Antigens
  • Hepatitis B virus / genetics
  • Hepatitis B* / complications
  • Hepatitis B* / epidemiology
  • Hepatitis B, Chronic* / complications
  • Humans
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / epidemiology
  • Neoplasm Recurrence, Local / epidemiology

Substances

  • DNA, Viral
  • Hepatitis B Core Antigens